Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Interrogating the roles of truncated/mutated inverted terminal repeat sequences in adeno-associated virus vectors in transgene stability through episome formation and host cell genome integration

Award Number: R01GM155648
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2026
PERIOD OF PERFORMANCE END DATE: 04/30/2030

Group Awards By:

View Award Description

Interrogating the roles of truncated/mutated inverted terminal repeat sequences in adeno-associated virus vectors in transgene stability through episome formation and host cell genome integration - PROJECT SUMMARY Gene therapies based on adeno-associated virus (AAV) vectors have been a revolutionary medical advancement in treating human genetic diseases. With a single dose, AAV-mediated gene therapies can confer long-term correction or abatement of disease for the lifetime of the patient. However, recent findings have found that vector DNA integration into the host-cell genome occurs at much higher frequencies than previously thought. Furthermore, integrated transgenes seem to substantially contribute to the long-term stable expression of the therapy. These reports have drastically shifted the safety status of AAVs. The only viral elements retained in AAV vectors used in gene therapy are the inverted terminal repeat (ITR) sequences found at both the ends of the vector genome. The ITRs are essential for the stability for the AAV vector genome after entry into the host cell. We recently revealed that vectors manufactured for gene therapy can harbor truncated or mutated (t/m)ITRs with fairly high frequencies. Interestingly, these types of imperfect ITRs match the truncated ITRs observed in integration sites. I, therefore, hypothesize that truncated/mutated ITRs in AAV viruses and in packaged vectors can influence the frequency of integration. This project proposal is divided into three main aims to define if and how truncated/mutated ITRs can alter the outcomes of AAV genomes, with paradigm-shifting implications for AAV-based gene therapy applications. • Aim 1: To examine ITR structures among wildtype AAVs. Examination of wildtype ITRs, which are proven to also integrate into the host cell infected with AAV, will help to inform on how ITR integrity in gene therapy vectors influences integration. We will perform advanced NGS-based identification of ITRs among natural proviral AAV genomes found in non-human primate tissues and test the ability of wtAAVs to spontaneously form t/mITRs. • Aim 2: To track the post-entry outcomes of vectors that bear a high percentage of t/mITRs. We will test vectors that harbor t/mITRs or wildtype (wt)ITRs for their ability to integrate into the host cell genome. We will develop novel cell culture and NGS-based workflows to interrogate t/mITR-mediated integration in cultured human hepatocytes and in humanized liver mouse models. • Aim 3: To find correlation between integration frequencies in treated non-human primate tissues with the prevalence of t/mITRs in test vectors. Examination of tissues from human patients receiving gene therapy is hard to justify. Non-human primate models are the best proxy to track the kinetics of integration. We will, therefore, examine tissues treated with AAV vectors sourced from previous studies to determine the rate of integration and the structure of ITRs in multiple treated tissues of NHPs.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $1,675,000 )
2026	2026	UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL	55 LAKE AVE N	WORCESTER	MA	01655	WORCESTER	USA	Biomedical Research and Research Training	000	1	4/10/2026	NEW	$1,675,000
														Subtotal = $1,675,000

Grand Total All Awards = $1,675,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Interrogating the roles of truncated/mutated inverted terminal repeat sequences in adeno-associated virus vectors in transgene stability through episome formation and host cell genome integration

Award Number: R01GM155648

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2026

PERIOD OF PERFORMANCE END DATE: 04/30/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer